List of Small Molecule Pharmaceuticals Companies in Taiwan - 11

Allgenesis is a privately-held, clinical stage ophthalmology company based in Taiwan. The company is focused on novel multi-specific fusion proteins for treating diabetic macular edema and wet-age-related macular degeneration; and small molecule eye drops for dry eye and pterygium diseases.

Anbogen Therapeutics is a clinical stage precision oncology company dedicated in developing first/best-in-class personalized therapeutics and making difference in patients' life. We bridge the gap between discovery candidates and proof-of-concept indications to challenge the unmet needs. Headquartered in Taiwan, we are advancing a pipeline of precision medicines for the treatment of solid tumors. Currently with three assets including ABT-101 and ABT-301 under clinical development.

Elixiron Immunotherapeutics is driven by a multi-cultural, international team in Shanghai, Taipei, the USA (San Francisco) and Switzerland (Lausanne) with a shared vision to build a global company that brings next-generation immunotherapies to patients in need. This vision drives our mission to target rare and immunological diseases as well as cancer for indications that could substantially benefit from advances in immunotherapy approaches. We employ advances in translational medicine to identify targets from clinical observations, and various drug modalities including biologics derived from a proprietary human antibody domain phage display library and a single human B cell antibody cloning platform to develop innovative therapies. Our two lead pipeline candidates are in phase 1 clinical trials. EI-1071, a small molecule inhibitor of CSF-1R kinase activity, is being explored as a potential therapy for Alzheimer's disease as well as tenosynovial giant cell tumors, and a monoclonal antibody, EI-001 is being developed for the treatment of vitiligo and other immunological disorders.

Eusol Biotech was founded in March 2005 in Taipei, Taiwan. The company is involved in the R&D and GMP process development of recombinant human acid fibroblast.

HuniLife Biotechnology, Inc. is a Taiwan-based biopharmaceutical company founded in 2013. HuniLife strives to develop efficacious new drugs and treatments to improve human health and well-being. The company focuses on drug pipelines, patents, clinical trials, and investment in the biopharmaceutical industry.

美時化學製藥股份有限公司（股票代碼：1795）成立於 1966 年，目前為台灣營收規模最大的製藥公司，也是一家全球性的製藥公司。美時專注於新藥和學名藥的商業化，致力爲患者提供更好、更安全、更易取得的藥品。公司擁有亞洲公認的一流研發和製造平台，並在包括美國、歐洲、日本、中國和巴西在內的幾乎所有全球市場建立了合作夥伴關係。美時在亞洲和美國進行超過 100 多個戰略選擇的製藥項目，其中包括 250 多種商業化產品。公司通過內部研發投資和合作授權，投資高門檻的腫瘤用藥、複雜學名藥以及 505（b）2 和 NCE 組成的多元化最佳產品組合，並透過戰略合作夥伴的支持下加強生物相似藥產品，以加强其產品組合競爭力。美時有亞洲地區最頂尖的研發中心與生產設備，也是台灣唯一同時獲得美國 FDA、歐盟 EMA、日本 PDMA、中國 FDA、及巴西 ANVISA 認證的藥廠。 Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with global presence, focused on commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. The Company has a recognized best-in-class R&D and manufacturing platform in Asia and has established partnerships in nearly every global market including the U.S., Europe, Japan, China, and Brazil. Lotus runs over 100 strategically selected pharmaceutical projects in development and registrations across Asia and the US, with over 250 commercial products. The Company invests in diversified best portfolio consisting of high-barrier oncology, complex generics as well as 505(b)2 and NCE via internal R&D investment and licensing-in partnership, and also strengthens its portfolio competitiveness by adding biosimilar products with support from strategic partners. Its industry-leading infrastructure certified by most of the advanced regulatory authorities around the world, including US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.

OEP Pharma is a full-service, global pharmaceutical company. Leveraging its R&D capabilities and commercial infrastructure in Asia, OEP Pharma develops, manufactures, and commercializes branded and generic medicines. OEP Pharma is the U.S. headquarters of OEP Group, a TWSE-listed pharmaceutical company founded in Taiwan in 1982. With a market cap of $200 million USD and 1000 employees worldwide, OEP has a 40-year track record as a distributor of choice in Taiwan and ASEAN countries. Today, OEP has a growing generics and specialty pharma product portfolio and pipeline, experienced salesforce in 10 countries, and distribution partners in North America. Its FDA-approved oral dosage facility, and injectables facility (FDA approval expected early 2021) specialize in complex formulations, including highly potent compounds, modified release products, and poorly soluble compounds.

Oneness Biotech is dedicated to fulfilling unmet medical needs by developing new drugs focused on chronic disorders in dermatology and immunology

PharmaEssentia Corporation, based in Taipei, Taiwan, is a rapidly growing, fully integrated global biopharmaceutical innovator. Leveraging proven scientific principles and deep expertise in commercializing medicines, the company aims to deliver biologics for challenging diseases in hematology, oncology and immunology, with one approved product and a diversifying pipeline. Founded in 2003, the company is now expanding its global presence with operations in the U.S., Japan, China and Korea.

TaiMed Biologics, founded in 2007, is a leading biopharmaceutical developer and manufacturer in Taiwan. We have extensive monoclonal antibodies (mAb) development and manufacturing experiences and have successfully developed and commercially launched the first and only mAb for HIV treatment in the US and Europe (Brand name: Trogarzo®). We are proud to offer Contract Development and Manufacturing Organization (CDMO) services for biopharmaceutical companies to propel your important monoclonal antibody molecules from development to market launch.

TaiRx, Inc. was founded in 2011 under the strategic alliance of Formosa Laboratories, Inc. and Efficient Pharma Management Corporate to develop a new generation of oncology molecule. In 2013, TaiRx started a series of financing and expanded the drug pipeline. In addition to cancer treatment, we also extended our reach to the therapy of other major diseases. TaiRx has a rich product pipeline and many of our products are moving rapidly into various clinical stages to ensure the safety and efficacy of the drug products. TaiRx continues to search for novel cures for serious diseases and deliver them to the medical community to help those in need. With Taiwan as our home base, we have successfully recruited many experts and consultants in new drug development worldwide. With our extensive experience and expertise in drug development, we can rapidly add value to our product line by moving the progress of our drug products forward. We are committed to our pursuit of high quality and scientific excellence, and establishing global collaboration and partnering. Our goal is to become a global drug development company and deliver new therapeutic hopes for the severe diseases.